By Anthony Silva, WBZ NewsRadio 1030 New England Business Editor

BOSTON (CBS) – A medical conference in San Francisco is still buzzing in reaction to some positive clinical results from a Cambridge biotech which is trying to attack a disease that kills children.

Sarepta Therapeutics says its first ever investigational drug for Duchenne Muscular Dystrophy is showing real promise.

Sarepta CEO Chris Garabedian tells me it’s one of the most severe forms of Muscular Dystrophy.

“It’s 100% fatal. It affects mostly boys, and they usually pass away in their late teens and early 20s,” Garabedian says.

He says he and his team have been working for years to find a way to stop or slow the progression of Duchenne.

“We have over two years of data that show we’ve generally stabilized the walking ability of these patients in our study,” he adds.

Garabedian also thinks the technology could be transferable to other diseases.

“We just talked about how we can modulate protein expression and gene translation across a lot of different applications in the neuromuscular diseases, other rare diseases, and we think this technology could even help with oncology or immune inflammatory diseases.”

Comments (4)

Leave a Reply

Please log in using one of these methods to post your comment:

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s